Following on from information provided to NICE by the company in December 2021, the appraisal of Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma [ID3862] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
Status | Discontinued |
Technology type | Medicine |
Decision | Selected |
Process | TA |
ID number | 3862 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
16 December 2022 | Discontinued. Following on from information provided to NICE by the company in December 2021, the appraisal of Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma [ID3862] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
24 December 2021 | Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma. Following discussion with the company, NICE has agreed to suspend this technology appraisal from the current work programme and updated timelines are to be confirmed. NICE will continue to monitor the situation and will update interested parties as and when the situation changes. |
16 November 2021 | Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma has now been rescheduled into the work programme. The appraisal is due to start early March 2022 and will be discussed at committee in early November 2022. The new timelines are subject to the work programme capacity and we will continue to review our plans in collaboration with the company and update our stakeholders accordingly. |
16 June 2021 | Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course. |
12 February 2021 - 12 March 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
10 March 2021 | The Department for Health and Social Care has asked NICE to conduct an appraisal of Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-August 2021 when we will write to you about how you can get involved. |
05 December 2017 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual